中國核能科技(00611.HK)中期擁有人應占溢利6091.9萬港元 同比增加約35.1%
格隆匯8月30日丨 中國核能科技(00611.HK)公吿,截至2023年6月30日止6個月中期業績,收益9.098億港元,同比減少25.7%;公司擁有人應占溢利為港幣6091.9萬元,相對去年同期增加約35.1%。期內每股基本盈利為3.29港仙,而截至2022年6月30日止6個月則為3.07港仙。
儲能是集團新能源戰略的重要補充,投資儲能項目也是集團推動業務多元化、行業細分化的關鍵舉措,集團未來也將順應市場變化,在儲能市場競爭尚不充分的情況下,提前佈局規劃、尋找業務機會,進一步拓展新能源業務範圍,提升集團在新能源行業綜合競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.